https://www.selleckchem.com/products/eft-508.html
To evaluate long-term durability of blinatumomab, a BiTE® (bispecific T-cell engager) molecule, in adults with relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukaemia (ALL). In this final analysis of an open-label, single-arm, phase 2, multicentreALCANTARA study (NCT02000427), adults (age ≥18 years) with Ph+ALL who had relapsed or were refractory to at least one TKI were included. The primary endpoint was the proportion of patients who achieved complete remission (CR)/CR with parti
Like
Comment
Share
